ArticleCureus2026
Subsequent Treatments After Progression on Cyclin-Dependent Kinase 4/6 Inhibitors: A Review of the Evidence and a Real-World Data Perspective From Portuguese Hospitals.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe treatment with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) (ribociclib, palbociclib, and abemaciclib) combined with endocrine therapy (ET) has become the standard of care (SoC) for first-line treatment in patients with metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer. There is a lack of consensus on what treatment to offer after disease progression, and there are no established guidelines for therapeutic sequencing.
objectiveThis multicentric retrospective observational analysis aims to characterize systemic treatment following CDK4/6i, among patients with HR+/HER2- metastatic breast cancer (MBC). MATERIALS AND
methodsAn observational retrospective study performed in 10 Portuguese oncological centers evaluated 237 patients with MBC who had been treated with at least one CDK4/6i, between January 2016 and July 2022, and had progressed with this treatment. We collected data on the initial staging, the date of diagnosis, HR status, Ki67 and HER2, the date of recurrence, metastatic site, the type of treatment, the date of initiation and the date of progression, and the reason for interruption.
resultsRechallenging with a different CDK4/6 inhibitor demonstrated the highest overall survival (OS), though it is used in a small percentage of patients, highlighting a potential survival advantage and the need for further investigation into optimal sequencing strategies. While capecitabine showed favorable progression-free survival (PFS) and overall survival, ET alone provided a higher OS, reflecting the influence of disease phenotype and treatment selection. Paclitaxel's shorter survival outcomes likely indicate its use in patients with aggressive disease or visceral crisis. These findings underscore the variability in survival outcomes based on post-CDK4/6i therapy choices in HR+/HER2- MBC, with promising evidence for rechallenging strategies.
conclusionSwitching CDK4/6i and ET conferred a statistically significant improvement of PFS in patients with progression or recurrence on prior CDK4/6i-containing therapy. These findings underscore the variability in survival outcomes based on post-CDK4/6i therapy choices in HR+/HER2- MBC, with promising evidence for rechallenging strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.